Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives

Journal of Medicinal Chemistry

Volumn 50, Issue 11, 2007, Pages 2655-2664

  Bichlmaier, Ingo ^a   Kurkela, Mika ^a   Joshi, Tanmaya ^a,b   Siiskonen, Antti ^a   Rüffer, Tobias ^c   Lang, Heinrich ^c   Suchanová, Bohumila ^a   Vahermo, Mikko ^a   Finel, Moshe ^a   Yli Kauhaluoma, Jari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

^c CHEMNITZ UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; GLUCURONOSYLTRANSFERASE; HYDROLASE INHIBITOR; ISOENZYME; ISOLONGIFOLOL; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLOGRAPHY; DRUG GLUCURONIDATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT;

CRYSTALLOGRAPHY, X-RAY; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SESQUITERPENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34250181284     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061204e     Document Type: Article

References (51)

1. Radominska-Pandya, A.; Ouzzine, M.; Fournel-Gigleux, S.; Magdalou, J. Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol. 2005, 400, 116-147.
2. Wells, P. G.; Mackenzie, P. I.; Chowdhury, J. R.; Guillemette, C.; Gregory, P. A.; Ishii, Y.; Hansen, A. J.; Kessler, F. K.; Kim, P. M.; Chowdhury, N. R.; Ritter, J. K. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 2004, 32, 281-290.
3. Fisher, M. B.; Paine, M. F.; Strelevitz, T. J.; Wrighton, S. A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 2001, 33, 273-297.
4. Owens, I. S.; Basu, N. K.; Banerjee, R. UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol. 2005, 400, 1-22.
5. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup. J.; Ball, S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 2004, 32, 1201-1208.
6. The term catalytic promiscuity has been used to describe the ability of an enzyme to catalyze an adventitious secondary activity at the active site responsible for the primary activity. However, in the case of metabolic enzymes like UGTs, the term has been used to depict their overlapping substrate selectivities. Cf. Copley, S. D. Enzymes with extra talents: moonlighting functions and catalytic promiscuity. Curr. Opin. Chem. Biol. 2003, 7, 265-272.
7. Court, M. H. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol. 2005, 400, 104-116.
8. Lightstone, F. C.; Ya-Jun, Z.; Maulitz, A. H.; Bruice, T. C. Non-enzymatic and enzymatic hydrolysis of alkyl halides: a haloalkane dehalogenation enzyme evolved to stabilize the gas-phase transition state of an SN2 displacement reaction. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 8417-8420.
9. Markham, G. D.; Parkin, D. W.; Mentch, F.; Schramm, V. L. A kinetic isotope effect study and transition state analysis of the S- adenosylmethionine synthetase reaction. J. Biol. Chem. 1987, 262, 5609-5615.
10. Schramm, V. L. Enzymatic transition states: thermodynamics, dynamics and analogue design. Arch. Biochem. Biophys. 2005, 433, 13-26.
11. Taylor Ringia, E. A.; Schramm, V. L. Transition states and inhibitors of the purine nucleoside phosphorylase family. Curr. Top. Med. Chem. 2005, 5, 1237-1258.
12. Grancharov, K.; Naydenova, Z.; Lozeva, S.; Golovinsky, E. Natural and synthetic inhibitors of UDP-glucuronosyltransferase. Pharmacol. Ther. 2001, 89, 171-186.
13. Timmers, C. M.; Dekker, M.; Buijsman, R. C.; van der Marel, G. A.; Ethell, B.; Anderson, G.; Burchell, B.; Mulder, G. J.; van Boom, J. H. Synthesis and inhibitory effect of a trisubstrate transition state analog for UDP glucuronosyltransferases. Bioorg. Med. Chem. Lett. 1997, 7, 1501-1506.
14. Noort, D.; Meijer, E. A.; Visser, T. J.; Meerman, J. H. N.; van der Marel, G. A.; van Boom, J. H.; Mulder, G. J. Selective inhibition of glucuronidation by 2,2,2-triphenylethyl-UDP in isolated rat hepatocytes: conjugation of harmol, 3,3′,5-triiodothyronine, and N-hydroxy-2- acetylaminofluorene. Mol. Pharmacol. 1991, 40, 316-320.
15. Schramm, V. L. Enzymatic transition states and transition state analogues. Curr. Opin. Struct. Biol. 2005, 15, 604-613.
16. Schramm, V. L. Enzymatic transition states and transition state analog design. Annu. Rev. Biochem. 1998, 67, 693-720.
17. Said, M.; Noort, D.; Magdalou, J.; Ziegler, J. C.; van der Marel, G. A.; van Boom, J. H.; Mulder, G. J.; Siest, G. Selective and potent inhibition of different hepatic UDP-glucuronosyltransferase activities by ω,ω, ω-triphenylalcohols and UDP derivatives. Biochem. Biophys. Res. Commun. 1992, 187, 140-145.
18. Noort, D.; Coughtrie, M. W.; Burchell, B.; van der Marel, G. A.; van Boom, J. H.; van der Gen, A.; Mulder, G. J. Inhibition of UDP- glucuronosyltransferase activity by possible transition-state analogues in rat-liver microsomes. Eur. J. Biochem. 1990, 188, 309-312.
19. Uchaipichat, V.; Mackenzie, P. I.; Elliot, D. J.; Miners, J. O. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2006, 34, 449-456.
20. Sell, C. S. A fragrant introduction to terpenoid chemistry; The Royal Society of Chemistry: Cambridge, U.K., 2003; pp 203-214.
21. Corey, E. J.; Ohno, M.; Vatakencherry, P. A.; Mitra, R. B. Total synthesis of D,L-longifolene. J. Am. Chem. Soc. 1961, 83, 1251-1253.
22. Volkmann, R. A.; Andrews, G. C.; Johnson, W. S. Novel synthesis of longifolene. J. Am. Chem. Soc. 1975, 97, 4777-4779.
23. Schultz, A. G.; Puig, S. The intramolecular diene-carbene cycloaddition equivalence and an enantioselective Birch reduction-alkylation by the chiral auxiliary approach. Total synthesis of (±)-and (-)-longifolene. J. Org. Chem. 1985, 50, 915-916.
24. Jadhav, P. K.; Brown, H. C. Dilongifolylborane: a new effective chiral hydroborating agent with intermediate steric requirements. J. Org. Chem. 1981, 46, 2988-2990.
25. Dimitrov, V.; Linden, A.; Hesse, M. Chiral ferrocenes derived from (+)-longifolene - determination of the configuration by NMR spectroscopy and X-ray crystallography. Tetrahedron: Asymmetry 2001, 12, 1331-1335.
26. Arigoni, D. Stereochemical aspects of sesquiterpene biosynthesis. Pure Appl. Chem. 1975, 41, 219-245.
27. Yoshikuni, Y.; Ferrin, T. E.; Keasling, J. D. Designed divergent evolution of enzyme function. Nature 2006, 440, 1078-1082.
28. Koistinen, J.; Lehtonen, M.; Tukia, K.; Soimasuo, M.; Lahtiperä, M.; Oikari, A. Identification of lipophilic pollutants discharged from a Finnish pulp and paper mill. Chemosphere 1998, 37, 219-235.
29. Passino-Reader, D. R.; Hickey, J. P.; Ogilvie, L. M. Toxicity to Daphnia pulex and QSAR predictions for polycyclic hydrocarbons representative of Great Lakes contaminants. Bull. Environ. Contam. Toxicol. 1997, 59, 834-840.
30. Ishida, T.; Asakawa, Y.; Takemoto, T. Hydroxyisolongifolaldehyde: a new metabolite of (+)-longifolene in rabbits. J. Pharm. Sci. 1982, 71, 965-966.
31. Rubio, J.; Calderon, J. S.; Flores, A.; Castroa, C. Trypanocidal activity of oleoresin and terpenoids isolated from Pinus oocarpa. Z. Naturforsch. C 2005, 60, 711-716.
32. Sawaikar, D. D.; Sinha, B.; Hebbalkar, G. D.; Sharma, R. N.; Patwardhan, S. A. Products active on mosquitoes. Part VII. Synthesis and biological activity of longifolene derivatives. Indian J. Chem. B 1995, 34, 832-835.
33. Choudhary, M. I.; Musharraf, S. G.; Nawaz, S. A.; Anjum, S.; Parvez, M.; Fun, H.-K.; Atta-ur-Rahman. Microbial transformation of (-)-isolongifolol and butyrylcholinesterase inhibitory activity of transformed products. Bioorg. Med. Chem. Lett. 2005, 13, 1939-1944.
34. Bichlmaier, I.; Siiskonen, A.; Finel, M.; Yli-Kauhaluoma, J. Stereochemical sensitivity of the human UDP-glucuronosyltransferases 2B7 and 2B17. J. Med. Chem. 2006, 49, 1818-1827.
35. Bichlmaier, I.; Siiskonen, A.; Kurkela, M.; Finel, M.; Yli-Kauhaluoma, J. Chiral distinction between the enantiomers of bicyclic alcohols by UDP-glucuronosyltransferases 2B7 and 2B17. Biol. Chem. 2006, 387, 407-416.
36. Bichlmaier, I.; Kurkela, M.; Siiskonen, A.; Finel, M.; Yli-Kauhaluoma, J. Eudismic analysis of tricyclic sesquiterpenoid alcohols. Lead structures for the design of potent inhibitors of the human UDP-glucuronosyltransferase 2B7. Bioorg. Chem. (submitted).
37. Ladziata, U.; Zhdankin, V. V. Hypervalent iodine(V) reagents in organic synthesis. ARKIVOC: Arch. Org. Chem. 2006, ix, 26-58.
38. Frigerio, M.; Santagostino, M.; Sputore, S. A user friendly entry to 2-iodoxybenzoic acid (IBX). J. Org. Chem. 1999, 64, 4537-4538.
39. Mizuta, T.; Sakaguchi, S.; Ishii, Y. Catalytic reductive alkylation of secondary amine with aldehyde and silane by an iridium compound. J. Org. Chem. 2005, 70, 2195-2199.
40. Concellon, J. M.; Cuervo, H.; Fernandez-Fano, R. An improved preparation of epoxides from carbonyl compounds by using diiodomethane/methyllithium: synthetic applications. Tetrahedron 2001, 57, 8983-8987.
41. Li, Z.; Racha, S; Dan, L.; El-Subbagh, H.; Abushanab, E. A general and facile synthesis of β- and γ-hydroxyphosphonates from epoxides. J. Org. Chem. 1993, 58, 5779-5783.
42. 2-terminal protein kinase with antiproliferative effects in neuronal tumor cells. J. Med. Chem. 2004, 47, 2710-2713.
43. Chandran, S. S.; Frost, J. W. Aromatic inhibitors of dehydroquinate synthase: Synthesis, evaluation and implications for gallic acid biosynthesis. Bioorg. Med. Chem. Lett. 2001, 11, 1493-1496.
44. Parrish, J. D.; Shelton. D. R.; Little, R. D. Titanocene(III)-promoted Reformatsky additions. Org. Lett. 2003, 5, 3615-3617.
45. Alternatively, gNOESY experiments could be used for the assignment of the absolute configuration at C(1′). The NOE correlation between C(1′)OH and endo-C(10)H was present when the OH group was pointing toward endo-C(10)H. In contrast, this NOE correlation was not found in its corresponding epimer in which the OH group was pointing away from endo-C(10)H. However, these correlations were often difficult to assign due to signal overlap, and, therefore, gHSQC analysis was superior because all corresponding signals were resolved.
46. Copeland, R. A. Evaluation of enzyme inhibitors in drug discovery; John Wiley & Sons: Hoboken, NJ, 2005.
47. Kurkela, M.; Garcia-Horsman, A.; Luukkanen, L.; Mörsky, S.; Taskinen, J.; Baumann, M.; Kostiainen, R.; Hirvonen, J.; Finel, M. Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J. Biol. Chem. 2003, 278, 3536-3544.
48. Kaivosaari, S.; Salonen, J. S.; Mortensen, J.; Taskinen, J. High-performance liquid chromatographic method combining radiochemical and ultraviolet detection for determination of low activities of uridine 5′-diphosphate-glucuronosyltransferase. Anal. Biochem. 2001, 292, 178-187.
49. Sheldrick, G. M. Phase annealing in SHELX-90: direct methods for larger structures. Acta Crystallogr., Sect. A 1990, 46, 467-473.
50. Sheldrick, G. M. SHELXL-97, A program for crystal structure refinement; Göttingen, Germany, 1996.
51. Flack, H. D. On enantiomorph-polarity estimation. Acta Crystallogr., Sect. A 1983, 39, 876-881.